Open AccessAssociation between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study
Author(s) -
Hideto Ueki,
Takuji Hara,
Yasuyoshi Okamura,
Yukari Bando,
Tomoaki Taguchi,
Junya Furukawa,
Kiyoshi Harada,
Yuzo Nakano,
Masato Fujisawa
Publication year - 2022
Publication title -
investigative and clinical urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.653
H-Index - 14
eISSN - 2466-054X
pISSN - 2466-0493
DOI - 10.4111/icu.20220028
Subject(s) - sarcopenia , medicine , nivolumab , hazard ratio , renal cell carcinoma , proportional hazards model , skeletal muscle , confidence interval , oncology , biomarker , cancer , immunotherapy , biochemistry , chemistry
Two methods are used to identify sarcopenia by calculating skeletal muscle area on computed tomography: the skeletal muscle index (SMI) and the psoas muscle index (PMI). Programmed death (PD)-1 inhibitors are helpful in treating metastatic renal cell carcinoma (mRCC). However, there remains insufficient information regarding a clear and easy-to-use biomarker for predicting the response to PD-1 inhibitors in patients with mRCC. Therefore, we investigated the influence of sarcopenia on clinical outcomes in patients with mRCC undergoing treatment with nivolumab.